COPPER CHELATION-INDUCED REDUCTION OF THE BIOLOGICAL-ACTIVITY OF S-NITROSOTHIOLS

被引:89
作者
GORDGE, MP
MEYER, DJ
HOTHERSALL, J
NEILD, GH
PAYNE, NN
NORONHADUTRA, A
机构
[1] UCL, INST UROL & NEPHROL, LONDON, ENGLAND
[2] UCL, DEPT BIOCHEM & MOLEC BIOL, LONDON, ENGLAND
[3] UCL, COBBOLD LABS, LONDON, ENGLAND
关键词
S-NITROSOTHIOL; S-NITROSOGLUTATHIONE; S-NITROSOCYSTEINE; NITRIC OXIDE; COPPER; BATHOCUPROINE SULFONATE; PLATELET AGGREGATION; CYCLIC GMP;
D O I
10.1111/j.1476-5381.1995.tb13317.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The effect of copper on the activity of the S-nitrosothiol compounds S-nitrosocysteine (cysNO) and S-nitrosoglutathione (GSNO) was investigated, using the specific copper chelator bathocuproine sulphonate (BCS), and human washed platelets as target cells. 2 Chelation of trace copper with BCS (10 mu M) in washed platelet suspensions reduced the inhibition of thrombin-induced platelet aggregation by GSNO; however, BCS had no significant effect on the anti-aggregatory action of cysNO. BCS inhibited cyclic GMP generation in response to both cysNO and GSNO. 3 The effect of BCS was rapid (within 30 s), and could be abolished by increasing the platelet concentration to 500 x 10(9) 1(-1). 4 In BCS-treated platelet suspensions, the addition of Cu2+ ions (0.37-2.37 mu M) led to a restoration of both guanylate cyclase activation and platelet aggregation inhibition by GSNO. 5 The anti-aggregatory activity of GSNO was reduced in a concentration-dependent manner by the copper (I)-specific chelators BCS and neocuproine, and to a smaller extent by desferal. No effect was observed with the copper (II) specific chelator, cuprizone, the iron-specific chelator, bathophenanthroline sulphonate, or the broader-specificity copper chelator, D-penicillamine. 6 In both BCS-treated and -untreated platelet suspensions, cys NO was more potent than GSNO as a stimulator of guanylate cyclase. In BCS-treated platelet suspensions there was no significant difference between the anti-aggregatory potency of cysNO and GSNO; however, in untreated suspensions, GSNO was significantly more potent than cysNO. Thus, when copper was available, GSNO produced a greater inhibition of aggregation than cysNO, despite being a less potent activator of guanylate cyclase. 7 The breakdown of cysNO and GSNO was measured spectrophotometrically by decrease in absorbance at 334 nm. In Tyrode buffer, cysNO (10 mu M) broke down at a rate of 3.3 mu M min(-1). BCS (10 mu M) reduced this to 0.5 mu M min(-1). GSNO, however, was stable, showing no fall in absorbance over a period of 7 min even in the absence of BCS. 8 We conclude that copper is required for the activity of both cysNO and GSNO, although its influence on anti-aggregatory activity is only evident with GSNO. The stimulatory effect of copper is unlikely to be explained solely by catalysis of S-nitrosothiol breakdown. The enhancement by copper of th anti-aggregatory activity of GSNO, relative to cysNO, suggests that copper may be required for biological activity of GSNO which is independent of guanylate cyclase stimulation.
引用
收藏
页码:1083 / 1089
页数:7
相关论文
共 32 条
[1]  
Blair D., 1961, TALANTA, V7, P163
[2]  
Dawson R.M.C., 1986, DATA BIOCH RES, P399
[3]  
DIEHL H, 1958, COPPER REAGENTS CUPR
[4]   UNDERSTANDING THE CONTROVERSY OVER THE IDENTITY OF EDRF [J].
FEELISCH, M ;
POEL, MT ;
ZAMORA, R ;
DEUSSEN, A ;
MONCADA, S .
NATURE, 1994, 368 (6466) :62-65
[5]   ENDOGENOUS NITROGEN-OXIDES AND BRONCHODILATOR S-NITROSOTHIOLS IN HUMAN AIRWAYS [J].
GASTON, B ;
REILLY, J ;
DRAZEN, JM ;
FACKLER, J ;
RAMDEV, P ;
ARNELLE, D ;
MULLINS, ME ;
SUGARBAKER, DJ ;
CHEE, C ;
SINGEL, DJ ;
LOSCALZO, J ;
STAMLER, JS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :10957-10961
[6]   SOLUBLE GUANYLATE-CYCLASE PURIFIED FROM BOVINE LUNG CONTAINS HEME AND COPPER [J].
GERZER, R ;
BOHME, E ;
HOFMANN, F ;
SCHULTZ, G .
FEBS LETTERS, 1981, 132 (01) :71-74
[7]   PLATELETS FROM PATIENTS ON HEMODIALYSIS SHOW IMPAIRED RESPONSES TO NITRIC-OXIDE [J].
GORDGE, MP ;
NEILD, GH .
CLINICAL SCIENCE, 1992, 83 (03) :313-318
[10]  
IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739